JAK2 (janus kinase 2)

Identity

HGNC	JAK2
Location	9p24
	JAK2 (9p24) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. Laboratories willing to validate the probes are welcome : contact rocchi@biologia.uniba.it

DNA/RNA

Description

25 exons spanning roughly 140 kb of genomic DNA; 5402 bp pre-mRNA; 6 different transcripts, putatively encoding 4 different protein isoforms

Protein

Description	1132 amino acids; 130,7 kDa; JAK2 contains a central Src homology 2 (SH2) domain, and two C-terminal domains: a tyrosine kinase domain JH1 (also termed PTK or TyrKc domain), and a tyrosine kinase-like domain JH2 (also termed STYKc)
Expression	wide
Localisation	intracellular, possibly membrane associated
Function	protein tyrosine kinase of the non-receptor type that associates with the intracellular domains of cytokine receptors; JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin; it has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon
Homology	JAK2 belongs to the janus kinase subfamily; so far four mammalian JAKs have been identified (JAK1, JAK2, JAK3, and TYK2); human JAK2 is > 90% identical to the mouse and the rat JAK2 homologs.

Mutations

Somatic

A high proportion (> 50%) of patients with myeloproliferative disorders (MPD; (polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis - see below) carry a dominant gain-of-function V617F mutation in the JH2 kinase-like domain of JAK2. This mutation leads to deregulation of the kinase activity, and thus to constitutive tyrosine phosphorylation activity. The incidence of the V617F mutation in different studies ranges from 65-97% in polycythemia vera, from 41-57% in patients with essential thrombocythemia, and from 23-95% in patients with idiopathic myelofibrosis. In MPD the mutation is heterozygous in most patients and homozygous only in a minor subset. Mitotic recombination probably causes both 9p LOH and the transition from heterozygosity to homozygosity. The same mutation was also found in roughly 20% of Ph-negative atypical CML, in more than 10% of CMML, in about 15% of patients with megakaryocytic AML (AML M7), and 1/5 patients with juvenile myelomonocytic leukemia (JMML). The V617F mutation seems to occur exclusively in hematopietic malignancies of the myeloid lineage.

Implicated in

Entity	t(8;9)(p21-22;p24) / acute leukaemias -- > PCM1-JAK2
Disease	myeloid and lymphoid malignancies; predominantly atypical CML, but also found in (CEL), (secondary) AML, and MDS/MPD; thirteen cases described to date, all male, except for one childhood female case with erythroid leukemia with multiple bone tumors
Prognosis	highly variable; allogeneic stem cell transplantation may be the only curative treatment
Hybrid/Mutated Gene	5¹ PCM1 ­ 3¹ JAK2; only in some cases the reciprocal 5¹ JAK2 ­ 3¹ PCM1 is present
Abnormal Protein	almost the entire PCM1 protein containing multiple coiled-coil domains is fused to the tyrosine kinase C-terminal domains (JH2 and JH1) of JAK2
Oncogenesis	dimerization or oligomerization of the PCM1-JAK2 chimera through one or more of the coiled-coil motifs of PCM1 probably results in the constitutive activation of the tyrosine kinase domain of JAK2
Entity	t(9;12)(p24;p13) / acute leukaemias --> JAK2/ETV6
Disease	myeloid and lymphoid leukemias; only three cases described to date; one case each: childhood T-ALL, pre B-ALL, atypical CML
Prognosis	unknown
Hybrid/Mutated Gene	5' ETV6 - 3' JAK2
Abnormal Protein	in the atypical CML the N-terminal HLH of ETV6 is fused to the tyrosine kinase C-terminal domains (JH2 and JH1) of JAK2; in the B-ALL the same ETV6 domain is fused to part of the JH2 and the complete JH1 domain, and in the T-ALL case to the JH1 domain
Oncogenesis	it may be speculated that the HLH domain of ETV6 provides a dimerization interface to the kinase domain of JAK2, which activates JAK2; ETV6-JAK2 transgenic mice ­ generated using a T-ALL specific fusion construct - develop fatal CD8+ acute T-cell leukemia
Entity	t(9;22)(p24;q11.2) /MPD-- > JAK2-BCR
Disease	atypical CML; only one case described to date
Hybrid/Mutated Gene	5¹ BCR ­ 3¹ JAK2; absence of the reciprocal 5¹ JAK2 ­ 3¹ BCR
Abnormal Protein	the N-terminal coiled-coil domain of BCR is fused to the JH1 tyrosine kinase C-terminal domain of JAK2
Oncogenesis	constitutive activation of the tyrosine kinase domain of JAK2 mediated through oligomerization through the coiled-coil domain of BCR
Entity	Polycythemia vera / Essential thrombocythemia / Idiopathic thrombocythemia / Idiopathic myelofibrosis
Note	the V617F mutation in JAK2 could form the basis for a new molecular classification of myeloproliferative disorders
Disease	chronic myeloproliferative syndromes
Oncogenesis	a significant percentage of patients with myeloproliferative disorders carries a dominant gain of function V617F mutation in JAK2; this mutation seems to lead to deregulation of the kinase activity of JAK2, and thus to constitutive tyrosine phosphorylation activity, providing hematopoietic cells with a proliferative and survival advantage

Breakpoints

External links

	Nomenclature
HGNC	JAK2   6192
Entrez_Gene	JAK2  3717  Janus kinase 2 (a protein tyrosine kinase)
	Cards
Atlas	JAK98
GeneCards	JAK2
Ensembl	JAK2 [Search_View]   ENSG00000096968 [Gene_View]
Genatlas	JAK2
GeneLynx	JAK2
eGenome	JAK2
euGene	3717
	Genomic and cartography
GoldenPath	JAK2  -  9p24   chr9:4975245-5117995 +  9p24   [Description]    (hg18-Mar_2006)
Ensembl	JAK2 - 9p24 [CytoView]
NCBI	Mapview
OMIM	Disease map [OMIM]
HomoloGene	JAK2
	Gene and transcription
Genbank	AF001362 [ ENTREZ ]
Genbank	AF005216 [ ENTREZ ]
Genbank	AF058925 [ ENTREZ ]
Genbank	AK292525 [ ENTREZ ]
Genbank	AK308668 [ ENTREZ ]
RefSeq	NM_004972 [ SRS ]    NM_004972 [ ENTREZ ]
RefSeq	AC_000052 [ SRS ]    AC_000052 [ ENTREZ ]
RefSeq	AC_000141 [ SRS ]    AC_000141 [ ENTREZ ]
RefSeq	NC_000009 [ SRS ]    NC_000009 [ ENTREZ ]
RefSeq	NT_008413 [ SRS ]    NT_008413 [ ENTREZ ]
RefSeq	NW_001839149 [ SRS ]    NW_001839149 [ ENTREZ ]
RefSeq	NW_924062 [ SRS ]    NW_924062 [ ENTREZ ]
AceView	JAK2 AceView - NCBI
Unigene	Hs.656213 [ SRS ]    Hs.656213 [ NCBI ]     HS656213 [ spliceNest ]
Fast-db	1664 (alternative variants)
	Protein : pattern, domain, 3D structure
SwissProt	O60674 [ SRS]    O60674 [ EXPASY ]     O60674 [ INTERPRO ]     O60674 [ UNIPROT ]
Prosite	PS00660 FERM_1 [ SRS ]    PS00660 FERM_1 [ Expasy ]
Prosite	PS00661 FERM_2 [ SRS ]    PS00661 FERM_2 [ Expasy ]
Prosite	PS50057 FERM_3 [ SRS ]    PS50057 FERM_3 [ Expasy ]
Prosite	PS00107 PROTEIN_KINASE_ATP [ SRS ]    PS00107 PROTEIN_KINASE_ATP [ Expasy ]
Prosite	PS50011 PROTEIN_KINASE_DOM [ SRS ]    PS50011 PROTEIN_KINASE_DOM [ Expasy ]
Prosite	PS00109 PROTEIN_KINASE_TYR [ SRS ]    PS00109 PROTEIN_KINASE_TYR [ Expasy ]
Prosite	PS50001 SH2 [ SRS ]    PS50001 SH2 [ Expasy ]
Interpro	IPR000299 Band_4.1_N [ SRS ]    IPR000299 Band_4.1_N [ EBI ]
Interpro	IPR009127 JAK [ SRS ]    IPR009127 JAK [ EBI ]
Interpro	IPR009129 JAK2 [ SRS ]    IPR009129 JAK2 [ EBI ]
Interpro	IPR000719 Prot_kinase_core [ SRS ]    IPR000719 Prot_kinase_core [ EBI ]
Interpro	IPR017441 Protein_kinase_ATP_bd_CS [ SRS ]    IPR017441 Protein_kinase_ATP_bd_CS [ EBI ]
Interpro	IPR000980 SH2 [ SRS ]    IPR000980 SH2 [ EBI ]
Interpro	IPR001245 Tyr_pkinase [ SRS ]    IPR001245 Tyr_pkinase [ EBI ]
Interpro	IPR008266 Tyr_pkinase_AS [ SRS ]    IPR008266 Tyr_pkinase_AS [ EBI ]
Interpro	IPR016251 TyrPK_Jak [ SRS ]    IPR016251 TyrPK_Jak [ EBI ]
CluSTr	O60674
Pfam	PF07714 Pkinase_Tyr [ SRS ]    PF07714 Pkinase_Tyr [ Sanger ]    pfam07714 [ NCBI-CDD ]
Pfam	PF00017 SH2 [ SRS ]    PF00017 SH2 [ Sanger ]    pfam00017 [ NCBI-CDD ]
Smart	SM00295 B41 [EMBL]
Smart	SM00252 SH2 [EMBL]
Smart	SM00219 TyrKc [EMBL]
Prodom	PD000001 Prot_kinase[INRA-Toulouse]
Prodom	O60674 JAK2_HUMAN [ Domain structure ]   O60674 JAK2_HUMAN  [ sequences sharing at least 1 domain ]
Prodom	PD000001[INRA-Toulouse]
Prodom	O60674 JAK2_HUMAN [ Domain structure ]   O60674 JAK2_HUMAN  [ sequences sharing at least 1 domain ]
Blocks	O60674
PDB	2B7A [ SRS ]    2B7A [ PdbSum ],   2B7A [ IMB ]   2B7A [ RSDB ]
HPRD	00993
	Protein Interaction databases
DIP	O60674
IntAct	O60674
	Polymorphism : SNP, mutations, diseases
OMIM	147796;187950;254450;263300;600880;601626    [ map ]
GENECLINICS	147796;187950;254450;263300;600880;601626
SNP	JAK2 [dbSNP-NCBI]
SNP	NM_004972 [SNP-NCI]
SNP	JAK2 [GeneSNPs - Utah]  JAK2] [HGBASE - SRS]
HAPMAP	JAK2 [HAPMAP]
COSMIC	JAK2 [Somatic mutation (COSMIC-CGP-Sanger)]
TICdb	JAK2 [Translocation breakpoints In Cancer]
HGMD	JAK2
	General knowledge
Family Browser	JAK2 [UCSC Family Browser]
SOURCE	NM_004972
SMD	Hs.656213
SAGE	Hs.656213
Enzyme	2.7.10.2 [ Enzyme-Expasy ]   2.7.10.2 [ Enzyme-SRS ]   2.7.10.2 [ IntEnz-EBI ]   2.7.10.2 [ BRENDA ]   2.7.10.2 [ KEGG ]   2.7.10.2 [ WIT ]
GO	nucleotide binding [Amigo]  nucleotide binding
GO	protein tyrosine kinase activity [Amigo]  protein tyrosine kinase activity
GO	non-membrane spanning protein tyrosine kinase activity [Amigo]  non-membrane spanning protein tyrosine kinase activity
GO	Janus kinase activity [Amigo]  Janus kinase activity
GO	receptor binding [Amigo]  receptor binding
GO	ATP binding [Amigo]  ATP binding
GO	cytoskeleton [Amigo]  cytoskeleton
GO	protein amino acid phosphorylation [Amigo]  protein amino acid phosphorylation
GO	protein amino acid phosphorylation [Amigo]  protein amino acid phosphorylation
GO	apoptosis [Amigo]  apoptosis
GO	cell motility [Amigo]  cell motility
GO	enzyme linked receptor protein signaling pathway [Amigo]  enzyme linked receptor protein signaling pathway
GO	intracellular signaling cascade [Amigo]  intracellular signaling cascade
GO	tyrosine phosphorylation of STAT protein [Amigo]  tyrosine phosphorylation of STAT protein
GO	STAT protein nuclear translocation [Amigo]  STAT protein nuclear translocation
GO	mesoderm development [Amigo]  mesoderm development
GO	negative regulation of cell proliferation [Amigo]  negative regulation of cell proliferation
GO	endomembrane system [Amigo]  endomembrane system
GO	membrane [Amigo]  membrane
GO	kinase activity [Amigo]  kinase activity
GO	transferase activity [Amigo]  transferase activity
GO	myeloid cell differentiation [Amigo]  myeloid cell differentiation
GO	SH2 domain binding [Amigo]  SH2 domain binding
GO	membrane raft [Amigo]  membrane raft
BIOCARTA	IL12 and Stat4 Dependent Signaling Pathway in Th1 Development    [Genes]
BIOCARTA	TPO Signaling Pathway    [Genes]
BIOCARTA	Bioactive Peptide Induced Signaling Pathway    [Genes]
BIOCARTA	EPO Signaling Pathway    [Genes]
BIOCARTA	Erythropoietin mediated neuroprotection through NF-kB    [Genes]
BIOCARTA	Growth Hormone Signaling Pathway    [Genes]
BIOCARTA	Inhibition of Cellular Proliferation by Gleevec    [Genes]
BIOCARTA	IFN gamma signaling pathway    [Genes]
BIOCARTA	IL 3 signaling pathway    [Genes]
BIOCARTA	NO2-dependent IL 12 Pathway in NK cells    [Genes]
BIOCARTA	Chaperones modulate interferon Signaling Pathway    [Genes]
KEGG	Jak-STAT signaling pathway
KEGG	Adipocytokine signaling pathway
PubGene	JAK2
TreeFam	JAK2
CTD	3717 [Comparative ToxicoGenomics Database]
	Other databases
	Probes
Probe	Cancer Cytogenetics (Bari)
Probe	JAK2 Related clones (RZPD - Berlin)
	PubMed
PubMed	408 Pubmed reference(s) in LocusLink

Bibliography

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.

Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffˆ© M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA

Science (New York, N.Y.). 1997 ; 278 (5341) : 1309-1312.

PMID 9360930

Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P

Blood. 1997 ; 90 (7) : 2535-2540.

PMID 9326218

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.

Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Ilaria R Jr, Marynen P, Gilliland DG

The EMBO journal. 1998 ; 17 (18) : 5321-5333.

PMID 9736611

TEL-JAK2 transgenic mice develop T-cell leukemia.

Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT, Bernard O, Ghysdael J

Blood. 2000 ; 95 (12) : 3891-3899.

PMID 10845925

TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways.

Ho JM, Nguyen MH, Dierov JK, Badger KM, Beattie BK, Tartaro P, Haq R, Zanke BW, Carroll MP, Barber DL

Blood. 2002 ; 100 (4) : 1438-1448.

PMID 12149229

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi AM

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (10) : 1847-1849.

PMID 16079890

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Cancer Genome Project, Green AR

Lancet. 2005 ; 365 (9464) : 1054-1061.

PMID 15781101

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.

Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P

Oncogene. 2005 ; 24 (48) : 7248-7252.

PMID 16091753

Genetics of myeloid malignancies: pathogenetic and clinical implications.

Frˆhling S, Scholl C, Gilliland DG, Levine RL

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 ; 23 (26) : 6285-6295.

PMID 16155011

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.

Goerttler PS, Steimle C, Mˆ§rz E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL

Blood. 2005 ; 106 (8) : 2862-2864.

PMID 15985544

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.

Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wˆrmann B, Haase D, Bohlander SK

Genes, chromosomes & cancer. 2005 ; 44 (3) : 329-333.

PMID 16001431

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

James C, Ugo V, Le Couˆ©dic JP, Staerk J, Delhommeau F, Lacout C, Garˆßon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W

Nature. 2005 ; 434 (7037) : 1144-1148.

PMID 15793561

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP

Blood. 2005 ; 106 (10) : 3370-3373.

PMID 16037387

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC

Blood. 2005 ; 106 (6) : 2162-2168.

PMID 15920007

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC

The New England journal of medicine. 2005 ; 352 (17) : 1779-1790.

PMID 15858187

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, Passamonti F, Pietra D, Cazzola M, Skoda RC

Blood. 2005 ; 106 (10) : 3374-3376.

PMID 16081684

Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.

Lasho TL, Mesa R, Gilliland DG, Tefferi A

British journal of haematology. 2005 ; 130 (5) : 797-799.

PMID 16115143

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW

Blood. 2005 ; 106 (10) : 3377-3379.

PMID 16081687

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frˆhling S, Dˆhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG

Cancer cell. 2005 ; 7 (4) : 387-397.

PMID 15837627

JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia.

Johan MF, Goodeve AC, Bowen DT, Frew ME, Reilly JT

British journal of haematology. 2005 ; 130 (6) : page 968.

PMID 16156870

JAK the trigger.

Mahon FX

Oncogene. 2005 ; 24 (48) : 7125-7126.

PMID 16007127

PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.

Murati A, Gelsi-Boyer V, Adˆ©laˆŲde J, Perot C, Talmant P, Giraudier S, Lodˆ© L, Letessier A, Delaval B, Brunel V, Imbert M, Garand R, Xerri L, Birnbaum D, Mozziconacci MJ, Chaffanet M

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (9) : 1692-1696.

PMID 16034466

Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.

Pesu M, O'Shea J, Hennighausen L, Silvennoinen O

Molecular interventions. 2005 ; 5 (4) : 211-215.

PMID 16123535

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.

Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC

Cancer research. 2005 ; 65 (7) : 2662-2667.

PMID 15805263

JAKing up hematopoietic proliferation.

Shannon K, Van Etten RA

Cancer cell. 2005 ; 7 (4) : 291-293.

PMID 15837617

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes.

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A

Blood. 2005 ; 106 (4) : 1207-1209.

PMID 15860661

The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.

Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J

British journal of haematology. 2005 ; 130 (6) : 964-965.

PMID 16156866

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.

Tefferi A, Gilliland DG

Mayo Clinic proceedings. Mayo Clinic. 2005 ; 80 (7) : 947-958.

PMID 16007902

JAK2 in myeloproliferative disorders is not just another kinase.

Tefferi A, Gilliland DG

Cell cycle (Georgetown, Tex.). 2005 ; 4 (8) : 1053-1056.

PMID 15970705

JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia.

Tono C, Xu G, Toki T, Takahashi Y, Sasaki S, Terui K, Ito E

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (10) : 1843-1844.

PMID 16079889

Identification of an acquired JAK2 mutation in polycythemia vera.

Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ

The Journal of biological chemistry. 2005 ; 280 (24) : 22788-22792.

PMID 15863514

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written	02-1998	Jean-Loup Huret
Updated	09-2005	Sabine Strehl

Citation

This paper should be referenced as such :

Huret JL . JAK2 (janus kinase 2). Atlas Genet Cytogenet Oncol Haematol. February 1998 . URL : http://AtlasGeneticsOncology.org/Genes/JAK98.html

Strehl S . JAK2 (janus kinase 2). Atlas Genet Cytogenet Oncol Haematol. September 2005 . URL : http://AtlasGeneticsOncology.org/Genes/JAK98.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Mon Aug 11 21:14:43 2008